AICARExplore study findings
Why AICAR changed glucose entry in cultured fat cells
1 numbered sourceSource years 2025
Peptides are short chains whose amino acids are connected by peptide bonds. Their sequences can help them transmit a signal or bind a particular target. AICAR is a nonpeptide ribonucleoside that cells convert to a nucleotide called ZMP. A 2025 study used mouse-derived fat cells to ask whether AICAR could change their response to insulin through a pathway beyond the energy sensor AMPK. [1]
Insulin usually prompts cells to move a glucose transporter called GLUT4 to the cell surface. Once there, it helps glucose enter. The researchers found that AICAR reduced the amount of GLUT4 moved to the surface in response to insulin and reduced glucose uptake in the cultured fat cells. They did not find a reduction in the cells’ overall GLUT4 supply. This pointed to a problem with moving the transporter to where it works. [1]
The team compared AICAR with a separate compound, called 991, that activates AMPK through a different route. That comparison compound did not reproduce AICAR’s inhibitory effect. Additional tests showed that converting AICAR to ZMP was required for the observed response, whereas changing AMPK activity by itself did not reproduce it. The result makes a distinction between using a molecule as a tool to activate an enzyme and attributing all of that molecule’s effects to the enzyme. [1]
These were cultured fat cells with a defined insulin stimulus. In a person, blood sugar reflects many tissues and regulatory systems, including how much glucose the liver releases and how much muscle takes up. The direction of a glucose-transport result in these fat cells is therefore evidence about that model. It cannot by itself predict the direction of blood sugar change in people. [1]
Sources
Original works cited in this article. Links open the external record in a new tab.
